Kyntra Bio CEO reports tax share withholding

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

KYNTRA BIO, INC. CEO and director Thane Wettig reported a routine tax-related share disposition. On March 6, 2026, 277 shares of common stock were withheld by the issuer at $6.84 per share to satisfy taxes due upon the vesting of restricted stock units. After this withholding, Wettig held 24,403 common shares directly, and an additional 40 shares were held indirectly by his spouse.

Insider Trade Summary

Exercise Price or Tax Liability: 277 shares

Exercise Price or Tax Liability 2 txns

Insider Wettig Thane

Role CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	277	$6.84	$2K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 24,403 shares (Direct); Common Stock — 40 shares (Indirect, By spouse)

Footnotes (1)

F1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kyntra Bio CEO Thane Wettig report for FGEN?

Thane Wettig reported a tax-related disposition of 277 Kyntra Bio common shares. The issuer withheld these shares at $6.84 each to cover taxes arising from vested restricted stock units, rather than an open-market sale or discretionary trade.

Were Kyntra Bio (FGEN) shares sold on the market in this Form 4?

No open-market sale occurred in this Form 4. The 277 Kyntra Bio shares were withheld by the issuer to satisfy a tax obligation triggered by restricted stock unit vesting, which is a standard, non‑discretionary mechanism rather than a market trade.

How many Kyntra Bio shares does Thane Wettig hold after this reported transaction for FGEN?

After the tax withholding transaction, Thane Wettig directly holds 24,403 Kyntra Bio common shares. An additional 40 shares are reported as indirectly owned through his spouse, providing the total reported equity position in this Form 4 filing.

What does the tax-withholding code F mean in the Kyntra Bio Form 4 for FGEN?

Code F indicates shares were used to pay a tax obligation. In this case, 277 Kyntra Bio shares were withheld by the issuer when restricted stock units vested, settling taxes due instead of using cash, and not reflecting a voluntary stock sale.

Does this Kyntra Bio (FGEN) Form 4 show any remaining derivatives for Thane Wettig?

The filing’s derivative section is empty, indicating no derivative positions such as options or warrants are reported in this specific Form 4. The focus is solely on common stock holdings and the tax-withholding share disposition tied to restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/10/2026 - 05:41 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wettig Thane

(Last)

(First)

(Middle)

C/O KYNTRA BIO, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO

94133

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/06/2026		F		277⁽¹⁾	D	$6.84	24,403	D
Common Stock								40	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

	/s/ John Alden, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR